SemBioSys, Roslin Institute Make Proteins from GM Organisms

Biotechnology firm SemBioSys Genetics (Calgary, AB) says it has demonstrated that it can produce insulin for the treatment of diabetes by growing insulin in genetically modified (GM) safflower plants. The insulin is indistinguishable from human insulin, SemBioSys says. SemBioSys says its proprietary GM plant technology will revolutionize the economics associated with producing insulin. Eli Lilly, Novo Nordisk, and Sanofi-Aventis currently dominate the insulin market, which in 2005 was worth $7.2 billion. The company says its technology would reduce manufacturing...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers